Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of “Buy” from Brokerages

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has received a consensus recommendation of “Buy” from the five analysts that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of equities research analysts recently weighed in on ODTX shares. Wall Street Zen raised Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. TD Cowen started coverage on Odyssey Therapeutics in a report on Tuesday. They set a “buy” rating on the stock. Oppenheimer started coverage on Odyssey Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $40.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Odyssey Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday. They issued an “overweight” rating for the company.

Insider Transactions at Odyssey Therapeutics

In other news, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the insider directly owned 1,831,383 shares in the company, valued at approximately $32,964,894. The trade was a 43.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Shelley Chu acquired 11,111 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $18.00 per share, with a total value of $199,998.00. Following the completion of the transaction, the director owned 11,111 shares of the company’s stock, valued at approximately $199,998. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 4,183,777 shares of company stock worth $75,319,986 over the last ninety days.

Odyssey Therapeutics Stock Down 0.3%

Shares of NASDAQ ODTX traded down $0.05 during mid-day trading on Tuesday, hitting $16.96. 127,382 shares of the stock were exchanged, compared to its average volume of 330,139. Odyssey Therapeutics has a twelve month low of $15.35 and a twelve month high of $20.30.